Clinical Trial: A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Breast Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
Brief Summary:
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
Read more